HSK39004 Dry Powder Inhaler Simulant

DRUG2 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

COPD (Chronic Obstructive Pulmonary Disease)Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Active, not recruitingNCT07108699

Haisco Pharmaceutical Group Co., Ltd.Chronic Obstructive Pulmonary Disease (COPD)

Start: 2025-08-13End: 2026-09-30Target: 180Updated: 2026-04-08

Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

RecruitingNCT07583849

Haisco Pharmaceutical Group Co., Ltd.COPD (Chronic Obstructive Pulmonary Disease)

Start: 2026-05-24End: 2027-10-30Target: 376Updated: 2026-06-10